#### 1 Title: Structural neurodevelopment at the individual level - a life-course investigation using

#### 2 ABCD, IMAGEN and UK Biobank data

3

Authors: Runye Shi<sup>1†</sup>, Shitong Xiang<sup>2,3†</sup>, Tianye Jia<sup>2,3,4,5†</sup>, Trevor W. Robbins<sup>2,3,6</sup>, Jujiao Kang<sup>2,3</sup>, Tobias Banaschewski<sup>7</sup>, Gareth J. Barker<sup>8</sup>, Arun L.W. Bokde<sup>9</sup>, Sylvane Desrivières<sup>10</sup>, Herta Flor<sup>11,12</sup>, Antoine Grigis<sup>13</sup>, Hugh Garavan<sup>14</sup>, Penny Gowland<sup>15</sup>, Andreas Heinz<sup>16</sup>, Rüdiger Brühl<sup>17</sup>, Jean-Luc Martinot<sup>18</sup>, Marie-Laure Paillère Martinot<sup>19</sup>, Eric Artiges<sup>20</sup>, Frauke Nees<sup>7,11,21</sup>, Dimitri Papadopoulos Orfanos<sup>13</sup>, Tomáš Paus<sup>22,23</sup>, Luise Poustka<sup>24</sup>, Sarah Hohmann<sup>7</sup>, Sabina Millenet<sup>7</sup>, Juliane H. Fröhner<sup>25</sup>, Michael N. Smolka<sup>25</sup>, Nilakshi Vaidya<sup>26</sup>, Henrik Walter<sup>16</sup>, Robert Whelan<sup>27</sup>, Gunter Schumann<sup>5,26</sup>, Xiaolei Lin<sup>1\*</sup>, Barbara J. Sahakian<sup>2,3,6\*</sup>, Jianfeng Feng<sup>1,2,3,28,29\*</sup>, IMAGEN Consortium

#### 11 Affiliations:

- <sup>1</sup> School of Data Science, Fudan University, Shanghai, China
- <sup>13</sup> <sup>2</sup> Institute of Science and Technology for Brain-Inspired Intelligence, Fudan University, Shanghai, China
- <sup>14</sup> <sup>3</sup> Key Laboratory of Computational Neuroscience and Brain-Inspired Intelligence (Fudan University), Ministry
- 15 of Education, China
- <sup>4</sup> Centre for Population Neuroscience and Precision Medicine (PONS), Institute of Psychiatry, Psychology &
- 17 Neuroscience, SGDP Centre, King's College London, United Kingdom, SE5 8AF
- 18 <sup>5</sup>Centre for Population Neuroscience and Precision Medicine (PONS), Institute of Science and Technology for
- 19 Brain-Inspired Intelligence (ISTBI), Fudan University, Shanghai, China
- <sup>6</sup> Department of Psychology and Behavioural and Clinical Neuroscience Institute, University of Cambridge,
- 21 Cambridge, United Kingdom
- <sup>7</sup> Department of Child and Adolescent Psychiatry and Psychotherapy, Central Institute of Mental Health,
- 23 Medical Faculty Mannheim, Heidelberg University, Square J5, 68159 Mannheim, Germany
- <sup>8</sup> Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London,
- 25 United Kingdom
- <sup>9</sup> Discipline of Psychiatry, School of Medicine and Trinity College Institute of Neuroscience, Trinity College
- 27 Dublin, Dublin, Ireland
- <sup>10</sup> Centre for Population Neuroscience and Precision Medicine (PONS), Institute of Psychiatry, Psychology &
- 29 Neuroscience, SGDP Centre, King's College London, United Kingdom
- 30 <sup>11</sup> Institute of Cognitive and Clinical Neuroscience, Central Institute of Mental Health, Medical Faculty
- 31 Mannheim, Heidelberg University, Square J5, Mannheim, Germany
- <sup>12</sup> Department of Psychology, School of Social Sciences, University of Mannheim, 68131 Mannheim,
- 33 Germany
- 34 <sup>13</sup> NeuroSpin, CEA, Université Paris-Saclay, F-91191 Gif-sur-Yvette, France
- <sup>14</sup> Departments of Psychiatry and Psychology, University of Vermont, 05405 Burlington, Vermont, USA
- <sup>15</sup> Sir Peter Mansfield Imaging Centre School of Physics and Astronomy, University of Nottingham,
- 37 University Park, Nottingham, United Kingdom

- <sup>16</sup> Department of Psychiatry and Psychotherapy CCM, Charité Universitätsmedizin Berlin, corporate member
- 39 of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany;
- 40 <sup>17</sup> Physikalisch-Technische Bundesanstalt (PTB), Braunschweig and Berlin, Germany
- 41 <sup>18</sup> Institut National de la Santé et de la Recherche Médicale, INSERM U A10 "Trajectoires développementales
- 42 en psychiatrie"; Université Paris-Saclay, Ecole Normale supérieure Paris-Saclay, CNRS, Centre Borelli; Gif-
- 43 sur-Yvette, France
- 44 <sup>19</sup> Institut National de la Santé et de la Recherce Médicale, INSERM U A10 "Trajectoires développementales
- 45 & psychiatrie", University Paris-Saclay, Ecole Normale Supérieure Paris-Saclay, CNRS; Centre Borelli, Gif-
- 46 sur-Yvette, France; and AP-HP. Sorbonne Université, Department of Child and Adolescent Psychiatry, Pitié-
- 47 Salpêtrière Hospital, Paris, France
- 48 <sup>20</sup> Institut National de la Santé et de la Recherche Médicale, INSERM U A10 "Trajectoires développementales
- 49 en psychiatrie"; Université Paris-Saclay, Ecole Normale supérieure Paris-Saclay, CNRS, Centre Borelli, Gif-
- 50 sur-Yvette; and Psychiatry Department, EPS Barthélémy Durand, Etampes, France
- 51 <sup>21</sup> Institute of Medical Psychology and Medical Sociology, University Medical Center Schleswig-Holstein Kiel
- 52 University, Kiel, Germany
- 53 <sup>22</sup> Department of Psychiatry, Faculty of Medicine and Centre Hospitalier Universitaire Sainte-Justine,
- 54 University of Montreal, Montreal, Quebec, Canada
- 55 <sup>23</sup> Departments of Psychiatry and Psychology, University of Toronto, Toronto, Ontario, Canada
- <sup>24</sup> Department of Child and Adolescent Psychiatry and Psychotherapy, University Medical Centre Göttingen,
- 57 von-Siebold-Str. 5, 37075, Göttingen, Germany
- <sup>25</sup> Department of Psychiatry and Neuroimaging Center, Technische Universität Dresden, Dresden, Germany;
- <sup>26</sup> Centre for Population Neuroscience and Stratified Medicine (PONS), Department of Psychiatry and
- 60 Psychotherapy, Charité Universitätsmedizin Berlin, Germany
- 61 <sup>27</sup> School of Psychology and Global Brain Health Institute, Trinity College Dublin, Ireland
- 62 <sup>28</sup> MOE Frontiers Center for Brain Science, Fudan University, Shanghai, China
- 63 <sup>29</sup> Zhangjiang Fudan International Innovation Center, Shanghai, China
- 64
- 65 † These authors contributed equally to this work.
- 66 \* Correspondence authors.
- 67 Xiaolei Lin (Address: School of Data Science, Fudan University, Shanghai, 200433, China. Email:
- 68 <u>xiaoleilin@fudan.edu.cn</u>)
- 69 or
- 70 Barbara Sahakian (Address: Department of Psychology and Behavioural and Clinical Neuroscience Institute,
- 71 University of Cambridge, Cambridge, United Kingdom. Email: bjs1001@cam.ac.uk)
- 72 or

73 Jianfeng Feng (Address: Institute of Science and Technology for Brain-inspired Intelligence, Fudan University,

- 74 Shanghai, 200433, China. Email: jianfeng64@gmail.com)
- 75
- 76
- 77
- 78
- 79

#### 80 Abstract

81 Adolescents exhibit remarkable heterogeneity in the structural architecture of brain development. 82 However, due to the lack of large-scale longitudinal neuroimaging studies, existing research has 83 largely focused on population averages and the neurobiological basis underlying individual 84 heterogeneity remains poorly understood. Using structural magnetic resonance imaging from the 85 IMAGEN cohort (n=1,543), we show that adolescents can be clustered into three groups defined 86 by distinct developmental patterns of whole-brain gray matter volume (GMV). Genetic and 87 epigenetic determinants of group clustering and long-term impacts of neurodevelopment in mid-88 to-late adulthood were investigated using data from the ABCD, IMAGEN and UK Biobank 89 cohorts. Group 1, characterized by continuously decreasing GMV, showed generally the best 90 neurocognitive performances during adolescence. Compared to Group 1, Group 2 exhibited a 91 slower rate of GMV decrease and worsened neurocognitive development, which was associated 92 with epigenetic changes and greater environmental burden. Further, Group 3 showed increasing 93 GMV and delayed neurocognitive development during adolescence due to a genetic variation, 94 while these disadvantages were attenuated in mid-to-late adulthood. In summary, our study 95 revealed novel clusters of adolescent structural neurodevelopment and suggested that genetically-predicted delayed neurodevelopment has limited long-term effects on mental well-96 97 being and socio-economic outcomes later in life. Our results could inform future research on 98 policy interventions aimed at reducing the financial and emotional burden of mental illness.

99

100

101

#### 102 Keywords:

structural neurodevelopment; longitudinal magnetic resonance imaging; individual trajectory of
 neurodevelopment; genetic and environmental factors of brain development;

#### 105 **Main**

106 Adolescence is a critical and active period for brain reconstruction and maturation, with regional 107 changes of synaptic morphology, dendritic arborization, cortical cell firing and changes in neurochemical receptor affinity <sup>1-3</sup>. Clinical symptoms of many neuropsychiatric disorders start 108 109 to emerge during this period, including conduct disorder, mood disorder and schizophrenia<sup>4-7</sup>. 110 Structural neurodevelopment during adolescence is important for enhanced cognitive abilities 111 and mental well-being persisting into adulthood<sup>8-16</sup>. Population-based studies have shown that 112 adolescents exhibit remarkable heterogeneity in terms of structural neurodevelopment<sup>17-19</sup>, but 113 the neurobiological basis of the heterogeneity remains poorly understood. Most efforts have been 114 devoted to study the functional circuitry and structural composition of the brain and their associations with mental health disorders at the population level<sup>1,20-25</sup>. These pioneering studies 115 have leveraged large population cohorts and refined our understanding of the adolescent brain. 116 117 However, associations between behavioral patterns and trajectories of brain development vary at 118 the individual level and understanding the sources of variation remains imperative in the arena of public health and precision medicine<sup>12,18,26,27</sup>. 119

120

121 Large-scale longitudinal neuroimaging studies have enabled delineation of the dynamic changes 122 of individual brain morphology, by clustering adolescents according to their developmental 123 trajectories of neuroimaging-derived phenotypes. Similar approaches have yielded associations 124 between atypical brain structure and neuroanatomical variation across neuropsychiatric 125 disorders<sup>28</sup>. Neuroimaging biomarkers offered tremendous versatility to determine the 126 neuropathological mechanisms of neurodegenerative and mental illnesses<sup>29-33</sup>, but have yet not 127 been fully utilized for neurodevelopment. Structural magnetic resonance imaging (sMRI) 128 provides non-invasive measures of imaging-derived phenotypes, among which the 129 developmental courses of gray matter volume (GMV) were shown to be strongly associated with myelinogenesis and synaptic plasticity during adolescence<sup>34-38</sup>. Collectively, this raises the 130 131 possibility of identifying novel clusters of dynamic brain structure according to the growth 132 trajectories of whole-brain GMV architecture.

133

In this study, we aim to investigate the individual heterogeneity of adolescent brain development,potential genetic, epigenetic and environmental factors that could contribute to the heterogeneity,

and possible long-term impacts of the heterogeneous brain developmental patterns on the biological and social wellbeing later in life. To accomplish these goals, we employ a data-driven approach to cluster adolescents into groups with distinct whole-brain GMV developmental patterns using longitudinal neuroimaging data from the IMAGEN cohort that spanned the entire period of adolescence and early adulthood (schematic workflow in Fig. 1a). Both genome-wide and epigenome-wide association studies are conducted to dissect the genetic and epigenetic changes associated with each cluster.

143

144 **Results** 

#### 145 Developmental trajectories of whole-brain GMV during adolescence define three clusters.

146 We began by estimating the longitudinal trajectories of GMV in 44 brain regions of interest 147 (ROIs) (34 cortical and 10 subcortical ROIs) that spanned the whole brain of each adolescent 148 across baseline (at age 14y) and two follow-up scans (at age 19y and 23y) in the IMAGEN study, 149 adjusting for intracranial volume (ICV), sex, handedness and site (Methods). Individuals showed 150 strong heterogeneity and clustering patterns in terms of baseline total GMV and GMV 151 developmental trajectories (Supplementary Fig. 1). Next, we reasoned that neurobiologically 152 meaningful clusters could be explained by the developmental patterns in a subset of ROIs. 153 Therefore, we conducted dimension reduction via principal component analysis (PCA) and 154 selected the first 15 principal components (PCs), which explained 80% of the total variation in 155 whole-brain GMV trajectories, in the clustering analysis (Supplementary Table 1). The first and 156 second PCs defined two combinations of GMV trajectories over the entire brain that were 157 significantly associated with baseline total GMV (Supplementary Fig. 2a). However, they 158 exhibited different association patterns with items of the Cambridge Gambling Task, where PC1 159 was significantly associated with delay aversion (r = 0.07,  $P_{adj} = 0.30$ ) and risk adjustment (r = -160 0.08,  $P_{adj} = 0.020$ ), and PC2 was significantly associated with deliberation time (r = 0.1,  $P_{adj} =$ 161 0.003), overall betting (proportion bet) (r = 0.07,  $P_{adj} = 0.014$ ) and risk-taking (r = 0.08,  $P_{adj} =$ 162 0.008) (Supplementary Fig. 2b). These PCs were then used in the multivariate clustering to 163 identify groups of adolescents with distinct neurodevelopmental patterns.

164

165 Among 1,543 adolescents with at least two sMRI scans, our analyses identified three clusters of 166 structural neurodevelopment ( $P_{permutation} < 0.001$ ) (Supplementary Fig. 3). Group 1 consisted of

167 711 (46.1%) adolescents, had high baseline total GMV and continuously decreasing GMV at follow-ups, which was consistent with the population GMV developmental trend<sup>28</sup>. Group 2 168 169 included 765 (49.6%) adolescents and compared to Group 1, they had lower baseline total GMV, 170 lower peak GMV, and slower rate of GMV decrease. In addition, adolescents in Group 2 are 171 more likely to be older (Diff = 0.11y, P < 0.001) and be males (Diff = 9.5%, P < 0.001), have 172 lower parental education (P = 0.020 for maternal education; P=0.003 for paternal education) and 173 lower WISCIV full score at age 14 (Diff = -1.76, P = 0.011). The remaining 67 (4.3%) belonged 174 to Group 3, among whom we observed the lowest baseline total GMV and surprisingly 175 increasing GMV at follow-ups, which was opposite to the population developmental trend (Fig. 176 1b, Supplementary Fig. 4-6). Compared to Group 1, Adolescents in Group 3 are more likely to 177 have lower parental education (P = 0.015 for maternal education; P = 0.010 for paternal 178 education) and lower WISCIV full score at age 14 (Diff = -9.22, P < 0.001). The full 179 demographic and baseline characteristics for each group were provided in Supplementary Table 180 2. Since we aim to investigate group-specific brain developmental patterns in late childhood, we 181 further estimated the age-specific GMV growth rate in each ROI from age 5y to 25y in each 182 group (Methods) using population neurodevelopmental curve as a reference. Consistently we 183 observed continuously decreasing GMV in Group 1 and Group 2 (with slower rate of GMV 184 decrease in Group 2), and increasing GMV in Group 3 for most ROIs (Fig. 1c), indicating 185 delayed neurodevelopment and brain maturation in Group 3 compared to the other groups.

186

187 To understand the neurobiological basis of group heterogeneity, we next tested for differences in 188 whole-brain GMV development among these groups. We observed common delayed GMV 189 development in ROIs spanning the inferior temporal, middle temporal, lateral orbitofrontal, 190 precentral and superior frontal areas in Group 3 (relative to Groups 1/2) (Fig. 1d top and 191 Supplementary Table 3). Group 2 showed lower peak GMV and slower rate of GMV decrease in 192 ROIs spanning superior frontal, caudal middle frontal, rostral middle frontal, precentral and inferior parietal areas (relative to Group 1) (Fig. 1d bottom and Supplementary Table 3). These 193 194 are all among the last areas in the brain to mature and had been implicated to play a key role in 195 executive functions. This led us to ask whether variations in structural neurodevelopment could 196 predict the developmental trajectories of neurocognition and risk of neuropsychiatric disorders in 197 these groups.

198

# 199 Structural neurodevelopment predicts neurocognition and risk factors for neuropsychiatric200 disorders.

201 To investigate the association between neurodevelopment and executive functions, we tested for 202 differences of neurocognitive performance among these groups at baseline and at the last follow-203 up. Full results of these comparisons were provided in Supplementary Table 4. We found that 204 compared to Group 1, Group 3 with delayed neurodevelopment showed worse neurocognitive performance (Spatial Working Memory, Cambridge Gambling Task (CGT) and Stop Signal Task 205 206 (SST)) at baseline, but most of these items improved over time with brain maturation and 207 became statistically equivalent at the last follow-up (Fig. 2a and Supplementary Fig. 7a). This 208 can be predicted by the structural architecture of GMV development in Group 3, where 209 increasing GMV in the top discriminating ROIs showed positive correlation with improvements 210 of neurocognition (Supplementary Fig. 8 and Supplementary Table 5). In contrast, Group 2 with 211 slower rate of GMV decrease showed worsened neurocognitive performance (CGT and SST) at 212 the last follow-up relative to baseline (Fig. 2a and Supplementary Fig. 7b), which could be 213 predicted by the negative correlations between the GMV developmental trajectories in the top 214 discriminating ROIs and neurocognition (Supplementary Fig. 8 and Supplementary Table 6).

215

216 The delayed brain and neurocognitive development in Group 3 led us to ask whether these 217 adolescents had increased risk for neuropsychiatric disorders. Consistent with the improvements 218 of neurocognition, we observed decreased attention-deficit/hyperactivity disorder (ADHD) 219 symptoms, but increased depression symptoms in Group 3 (Fig. 2b and Supplementary Table 4). 220 This indicated that although neurocognitive abilities in Group 3 exhibited pronounced 221 improvement during adolescence, this was not necessarily the case for mental disorder symptoms. 222 Furthermore, consistent with their worsened neurocognitive performances, we observed 223 increased depression symptoms in Group 2 at the last follow-up compared to baseline, (Fig. 2b 224 and Supplementary Table 4). The continuously worsened neurocognition and mental health 225 problems in Group 2 indicated biological, social and mental disadvantages among these 226 adolescents.

227

228 Given the slightly different patterns of GMV development for males and females<sup>28</sup>, we 229 conducted the analyses stratified by sex following the same workflow. Results of group 230 clustering largely overlapped with the original analyses (Supplementary Table 7). In general, the 231 sex-stratified analyses revealed similar patterns of neurocognition and mental health symptoms 232 among three groups of adolescents. However, differences of neurocognition among these groups 233 were manifested more for risk-taking and impulsive behaviors in males, while for spatial 234 working memory in females (Supplementary Table 8). Besides, increase of the depressive 235 symptoms in Group 2 was only observed in males, and increase of the depressive symptoms in 236 Group 3 was only observed in females.

237

238 In addition, we compared the genetic liability to major neurodevelopmental disorders and related 239 traits, including ADHD, autism spectrum disorder (ASD), educational attainment (EA) and 240 intelligence (IQ), by calculating the corresponding polygenic risk scores (PRS) for each 241 adolescent. Group 3 had higher PRS for ADHD than both Group 1 ( $P_{adj} = 0.007$ ) and Group 2  $(P_{adi} = 0.017)$ , while Group 2 was not statistically different from Group 1 ( $P_{adj} = 0.42$ ). We did 242 243 not observe significant differences among the three groups in terms of the PRS of ASD, EA and 244 IQ (Supplementary Table 9). The higher genetic liability of ADHD in Group 3 led us to ask 245 whether genetic variants could explain the delayed neurodevelopment and neurocognitive 246 performances in this group.

247

#### 248 Genetic variation and epigenetic changes contribute to structural neurodevelopment.

249 To better understand the genetic basis of structural neurodevelopment, we conducted genome-250 wide association studies (GWAS) for Group 3 versus Groups 1/2 using group-reweighted GMV 251 as the proxy-phenotype among 7,662 adolescents in ABCD, since GWAS was under-powered 252 for the IMAGEN study due to limited sample size<sup>39</sup>. Group-reweighted GMV was derived and 253 used as the proxy phenotype because GMV developmental patterns could not be estimated in 254 ABCD due to limited age range. This continuous phenotype represented one's tendency of being 255 in Group 3 relative to Groups 1/2, or in other words, one's propensity of having delayed brain 256 development. Specifically, we began by calculating the ROI-specific weight in discriminating 257 Group 3 (relative to Groups 1/2) in IMAGEN adjusting for potential confounders, and applying 258 these weights to corresponding ROIs in ABCD to obtain the Group3-reweighted GMV, which

was then used as the proxy phenotype in the Group 3 GWAS (Methods). The Group3-reweighted GMV showed negative correlation with neurocognition in ABCD, indicating the validity of using Group3-reweighted GMV as appropriate proxy for delayed neurodevelopment (Fig. 3a and Supplementary Table 10). Similarly, Group2-reweighted GMV was calculated and used as the proxy phenotype in the Group 2 GWAS.

264

265 One locus showed genome-wide significant effects in the Group 3 GWAS (Fig. 3b and 266 Supplementary Table 11). The lead single-nucleotide polymorphisms (SNP), rs9375442 ( $\beta =$ 0.52,  $P = 1.02 \times 10^{-8}$ ) on chromosome 6, is an intronic variant located on CENPW (Supplementary 267 Fig. 9). CENPW is a protein-coding gene involved in the packaging of telomere ends and cell 268 269 cycle mitotic<sup>40,41</sup>, and increased *CENPW* expression in progenitors could lead to decreased cortical volume and cognitive function by altering neurogenesis or increasing apoptosis<sup>42</sup>. Other 270 271 variants on these genes were reported to be associated with cortical surface area and brain volume<sup>43-48</sup> (Supplementary Fig. 10), general cognitive ability<sup>49-51</sup> and physical growth<sup>52-56</sup>. 272 273 Gene-based association analysis confirmed the identification of CENPW (Supplementary Fig. 274 11). Next, we conducted validation of the Group 3 GWAS back in IMAGEN. We began by 275 calculating the polygenic risk score for SNPs ( $N_{SNP} = 4$ ) residing in CENPW (CENPW score) and 276 across the whole genome (PRS) that are associated with Group3-reweighted GMV for each 277 adolescent in IMAGEN, tested for the differences of PRS among these groups, and correlated the 278 PRS with neurocognition and behavioral risk factors. Consistent with the Group 3 GWAS, we 279 observed higher CENPW score in Group 3 relative to Groups 1/2 (Fig. 3c) and positive 280 correlations between CENPW score and improvement of neurocognition and conduct problems 281 (Fig. 3d). Similar results were obtained for PRS (Supplementary Fig. 12).

282

No genome-wide significant SNPs were identified in the Group 2 GWAS (Supplementary Fig. 13). However, the large overlap between the neurodevelopmental patterns and homogeneous genetic liability in Group 2 with Group 1 led us to reason that the differences of neurocognitive performances between Group 1 and 2 were quantitative (rather than qualitative) and might subject to the effects of environmental exposure. To test this, we performed epigenome-wide association studies (EWAS) in IMAGEN (Methods) using group label as the phenotype. A significant hypermethylation site cg06064461 ( $\beta = 25.40$ ,  $P = 4.24 \times 10^{-8}$ ) (Fig. 4a) was identified

290 and mapped to ATF2 and MIR933 on chromosome 2. ATF2 encodes a transcription factor of the 291 activator protein-1 family, is ubiquitously expressed in the brain and was found to be associated 292 with both neurodegeneration and neurogenesis<sup>57-59</sup>. MIR933 shares a common promoter with 293 ATF2 and offers neuroprotection against neurodegenerative diseases by regulating brain-derived 294 neurotrophic factor (BDNF)<sup>60</sup>. To validate the EWAS results, we correlated the methylation of 295 cg06064461 with estimated GMV trajectory and peak GMV in Groups 1/2, and calculated the 296 mediation effects of cg06064461 methylation in the adverse environment - neurodevelopment 297 pathway. Consistent with the EWAS results, positive correlation between cg06064461 298 methylation and total GMV trajectory (r = 0.14, P < 0.001) (Fig. 4b) and negative correlation 299 between cg06064461 methylation and peak GMV (r = -0.07, P = 0.020) (Fig. 4c) were observed. 300 Although none mediation effects of cg06064461 methylation on the environment -301 neurodevelopment pathway showed statistical significance after correcting for multiple testing 302 (Fig. 4d and Supplementary Table 12), nominal significance was observed for family affirmation, 303 where higher level of family affirmation was associated with higher peak GMV through reduced 304 cg06064461 methylation (Fig. 4e). Family affirmation was defined as behaviors that the parent 305 puts in place to support or help children in various situations or to show them approval and affection and refers to parent-child relationship<sup>61</sup>. These results indicated that environmental 306 307 exposure could contribute to disadvantaged neurodevelopment and neurocognition by inducing 308 epigenetic changes of neurogenesis-related genes.

309

## Genetic variation had limited effects on the cognitive, mental health and socio-economic outcomes in mid-to-late adulthood.

Both genetic vulnerability and structural neurodevelopment are well-established to have profound impact on one's physical, social and mental well-being in mid-to-late adulthood<sup>62-65</sup>. However, the neurobiological mechanisms through which the long-term effects of genetic variation could be manifested remain largely unknown. We conclude our study by testing in the UK Biobank whether, and to what degree, polygenic risk for delayed neurodevelopment could have impact on the long-term brain structure, cognition, social-economic outcomes and mental well-being.

319

320 Motivated by the Group 3 GWAS results, we first calculated the PRS and CENPW score of 321 delayed neurodevelopment for each participant in UK Biobank and then correlated them with 322 outcomes of interest. Both PRS and CENPW score were approximately normally distributed and 323 negatively associated with total GMV among this population (Fig. 5a). Next, we inspected the 324 association of PRS and CENPW score with GMV in multiple brain regions in UK Biobank and 325 found that inferior temporal, fusiform, middle temporal, medial orbitofrontal and lateral 326 orbitofrontal areas were among the most correlated ROIs with PRS of delayed neurodevelopment, 327 and lateral orbitofrontal, caudal middle frontal, rostral middle frontal, insula and superior frontal 328 areas were among the most correlated ROIs with CENPW score (Fig. 5b and Supplementary Tables 13-14). These were consistent with the worse spatial working memory among participants 329 330 with higher PRS of delayed neurodevelopment and CENPW score (Supplementary Table 15). 331 Finally, we conducted non-superiority tests of the correlation coefficients and found that 332 correlations between PRS of delayed neurodevelopment and CENPW score and all outcomes of 333 interest were smaller than 0.05 (Fig. 5c and Supplementary Figs. 14-15). This indicated that 334 although polygenic risks contributed to delayed neurodevelopment during adolescence, their 335 long-term influences on the cognitive, mental health and socio-economic outcomes were limited 336 once neurocognitive abilities were fully developed.

337

#### 338 Discussion

339 Adolescence is a dynamic maturational period characterized by potentially suboptimal decision 340 making and an amplified risk of behavioral problems due to the immature brain and cognitive abilities<sup>66-70</sup>. There is a growing consensus that adolescents have remarkably heterogeneous brain 341 342 developmental patterns<sup>18</sup>. Therefore, studies at the population average level may obscure the true 343 relationship between dynamic brain changes and risks for neuropsychiatric disorders. Here, we 344 developed a data-driven approach that identified three groups of adolescents with distinct whole-345 brain neurodevelopmental patterns, and showed that these groups had associated genetic or 346 epigenetic determinants, and could predict the paths of both neurocognitive development and 347 long-term socio-economic attainments and mental well-being in mid-to-late adulthood.

348

349 Both neuroimaging and animal studies show that gray matter in higher-order brain regions 350 undergoes continuous thinning during adolescence with synaptic pruning and

myelination<sup>25,28,71,72</sup>. Therefore, increasing gray matter during this period, especially in higher-351 352 order brain regions responsible for executive functions, is indicative of delayed brain maturation. 353 Furthermore, a slower rate of gray matter thinning suggests reduced density of synapses and 354 myelination<sup>3</sup>, which would further limit the enhancement of neurocognitive function and 355 efficient information processing<sup>69,73,74</sup>. These diverse growth trajectories of the adolescent brain 356 are capable of shifting both behaviors and the learning capabilities, in ways that could lead to 357 life-long impacts<sup>70,75-77</sup>. Further, human brain development involves continuing and complex interactions between genetic and environmental influences<sup>23,26,78-83</sup>. By integrating genomic, 358 359 neuroimaging, behavior and health-related data from three large-scale population cohorts, we 360 confirmed that genetic variants are associated with delayed brain maturation and neurocognitive 361 development, without affecting the socio-economic and mental well-being later in life. Whereas, 362 adverse environmental exposure and the associated epigenetic changes could lead to prolonged 363 negative effects on brain development and behavioral disadvantages. Importantly, we regard the 364 differences between Group 2 and Group 1 as quantitative and subject to the magnitude of cumulative adverse environmental exposure, as reflected by the large overlap in their 365 366 neurodevelopmental patterns and the relatively small effect sizes associated with adverse 367 environmental factors. Consolidating results from EWAS and mediation analysis, our study shed 368 light on the possible epigenetic and neurobiological mechanisms underlying potential causal 369 pathways between environmental exposure and adolescent brain development. However, it does 370 not necessarily mean that the differences between Group 3 and Group 1 could only be attributed 371 to genetic variation, or that differences between Group 2 and Group 1 was purely due to environment. Future research with larger sample size and adequate statistical power are needed 372 373 to elucidate the potential interplay between gene and environment on structural brain 374 development.

375

To our knowledge, this is the first attempt to investigate longitudinal brain development at the individual level and its associations with neurocognition and socio-economic outcomes persisting into late adulthood. The three population cohorts involved in our analyses were designed for relatively different purposes, in different populations and produced different data components. Although we tried to link the neurodevelopmental patterns from IMAGEN to ABCD and UK Biobank, this mapping using genetic and neuroimaging associations may subject

382 to confounding bias. For example, the bridging between IMAGEN and ABCD assumed a linear 383 change of GMV from 9 years old (baseline age for the majority participants in ABCD) to 14 384 years old (baseline age for the majority participants in IMAGEN), and homogenous population 385 composition between these two cohorts. Given the findings from existing investigations (give a 386 reference of brain chart), a linear trend of GMV from 9 to 14 years old were attainable, and in 387 order to achieve population homogeneity, we only selected participants of self-reported "White" 388 ethnicity in ABCD. In addition, both the appropriateness of using the proxy phenotype and 389 results of GWAS conducted in ABCD were successfully validated. However, validation of our 390 results, particularly the long-term impacts in mid-to-late adulthood, are required once long-term 391 follow-ups of socio-economic outcomes in these adolescents become available. Further, the 392 IMAGEN study involves healthy individuals only and our findings may have limited 393 generalizability to specific disease populations. Although these adolescents were not diagnosed 394 with specific neuropsychiatric disorders at baseline, they were likely to be present with 395 subclinical symptoms, referred to minor neurological abnormalities or dysfunction seen in the 396 absence of an obvious cause or pathology. Evidence indicated that subclinical symptoms seen in 397 normal young children were partly attributable to immaturity of the nervous system and were frequently found in the clinical course of psychosis<sup>84</sup>, schizophrenia<sup>85</sup> and Alzheimer's disease<sup>86</sup>. 398 399 Neuroimaging studies thus stand as a powerful tool for identifying important brain regions and 400 morphological phenotypes associated with subclinical symptoms, and for elucidating the 401 neurobiological correlates of subclinical symptoms along the course of brain development. 402 Finally, the three groups identified in this study constitute an initial attempt to solve the problem 403 of heterogeneous brain development that relies heavily on the image-derived phenotypes 404 obtained from sMRI. Further investigation using other neuroimaging modalities, or multi-modal 405 phenotypes are needed for a comprehensive understanding of this dynamic process.

406

#### 407 Methods

408 Participants Genomic, neuroimaging, environmental exposure, behavioral and mental health 409 related data used to identify adolescent neurodevelopmental patterns were obtained from the 410 IMAGEN study. Individuals with GMV beyond 4 interquartile ranges (IQRs) in any ROI were 411 considered as outliers and were excluded from the analyses. After applying the exclusion criteria, 412 1543 adolescents with at least two structural MRI scans from 14 to 23 years old were included in

413 the analyses (Supplementary Table 16). The average number of structural MRI scans per 414 participant was 2.63, with 974 adolescents having a total of 3 scans (at 14, 19 and 23 years, 415 respectively) and 569 adolescents having a total of 2 scans (384 at 14y and 19y, 147 at 14y and 416 23y and 38 at 19y and 23y). In addition, genotyping data used in GWAS, validation of GWAS 417 and investigation of the long-term impact were obtained from ABCD, IMAGEN and UK 418 Biobank, respectively. A total of 11,760 participants aged between 9 and 11 years old from 419 ABCD were included, with the average number of structural MRI scans per adolescent 1.68. 420 Further, 502,409 participants aged between 37 and 73 years old from UK Biobank were included 421 in the long-term analyses of structural brain development. Demographics and baseline 422 characteristics of participants from the three large population cohorts were summarized in 423 Supplementary Table 17. A full description of all population cohorts used in the analyses can be 424 found in Supplementary Methods.

425

#### 426 Analysis of Structural MRI data

427 Data preprocessing In brief, quality-controlled processed T1-weighted neuroimaging data were 428 obtained from ABCD, IMAGEN, Human Connectome Project Development (HCP-D), HCP 429 Young Adult (HCP-YA) and the Philadelphia Neurodevelopmental Cohort (PNC). Assessment 430 of regional morphometric structure were extracted by FreeSurfer v6.0 using Desikan-Killiany 431 (h.aparc) atlas for cortical regions, and ASEG atlas for subcortical regions. Quality check was 432 performed according to FreeSurfer reconstruction QC measures. Detailed description of data 433 collection and preprocessing is provided in Supplementary Methods.

434

Estimation of GMV developmental trajectory GMV trajectory in each of the 44 ROIs was estimated for each adolescent using linear mixed effect regression model (*lme4* 1.1-31 package) (since at most three structural MRI scans were available for each adolescent, only random slope model could be robustly estimated). Empirical Bayes estimate of the random slope was extracted for each adolescent. Intracranial volume (ICV), sex, handedness and imaging site were used as covariates to adjust for potential confounding.

441

442 Principal component analysis (PCA) and group clustering Dimension reduction via PCA was
 443 performed to individual GMV trajectories estimated in the 44 ROIs. The first 15 principal

components (Supplementary Table 1), which explained 80% of the total variation, were used in
the multivariate k-means clustering. The optimal number of clusters was selected based on
Elbow method with the constraint that each cluster contain at least 4% of the overall population.

448 Permutation test Permutation was conducted by shuffling the estimated GMV trajectory in each 449 ROI simultaneously and re-performing the dimension reduction and multivariate clustering 450 repeatedly over 1000 times. P value was calculated as the proportion of Between-cluster Sum of 451 Squares / Total Sum of Squares ratio greater than the estimated ratio in the original sample 452 across all 1000 permutations.

453

454 **Comparison of GMV trajectory among groups** Pairwise comparisons of GMV developmental 455 trajectories in each ROI among the three groups were conducted via t test. The top 5 ROIs with 456 the largest absolute t values were selected as the top distinguishing ROIs between the 457 corresponding groups (Supplementary Table 3). Cohen's ds (calculated using *effectsize* 0.8.3 458 package) for these regions were provided in Fig. 1d and Supplementary Fig. 16.

459

460 Estimation of age and region-specific GMV development among groups To illustrate the 461 region-specific GMV development in an extended time frame ranging from late childhood to 462 early adulthood, external neuroimaging data from several population cohorts were incorporated. 463 This includes a total of 21,826 participants comprising of 11,811 participants aged 9-14y with 464 19,587 scans in ABCD, 652 participants aged 5-22y in HCP-D, and 1,587 participants aged 8-465 23y in PNC study. Since cubic model could not capture GMV trajectory beyond 23y and 466 quadratic model could not utilize data before 9y, we used a reference curve estimated from cross 467 sectional studies (HCP-D + PNC) in estimating the region-specific GMV developmental curve 468 over 5-25y. Distance between GMV in IMAGEN and that in the reference population in the 469 corresponding ROI was used as the dependent variable in the quadratic linear mixed effect model 470 with random intercept and slope, adjusting for ICV and site. Empirical Bayes estimates of the 471 random effects for each group were added to the population averaged estimates to yield the 472 group-specific developmental curve.

473

474 Estimation of group-specific developmental curve of total GMV in IMAGEN A two-stage 475 estimating procedure was adopted. Optimal model was selected among a series of polynomial 476 mixed effect models using likelihood ratio test. First, population ICV developmental curve over 477 5-23y was estimated using the above-mentioned population neuroimaging data. Quadratic linear 478 mixed effect models with random intercept at the individual and study level were fitted. To 479 estimate the developmental curve of total GMV in the reference population (ABCD + HCP + 480 PNC), cubic model adjusting for ICV was selected with random intercepts at the individual and 481 study level. To estimate the developmental curve of total GMV in the ABCD and IMAGEN 482 population, cubic model adjusting for ICV was selected with random intercept and slope at the 483 individual level. Empirical Bayes estimates of the random effects were extracted and averaged in 484 each group. Population ICV estimated in stage 1 was used to fit group-specific curves. The 5<sup>th</sup> and 95th percentile of the group-specific total GMV were calculated as the 95% confidence 485 486 interval at each age.

487

488 Estimation of peak total GMV in IMAGEN To estimate the peak total GMV in the IMAGEN 489 population, 1, 113 participants aged 22-38y in HCP-YA study were added to the reference 490 population. A similar two-stage estimating procedure was used and the optimal model was 491 selected based on Bayesian information criterion (BIC) and likelihood ratio test. First, population 492 developmental curve of ICV was estimated using mixed effect regression model (nlme 3.1-160 493 package) with random intercept and slope. Basis function involving centered age was determined 494 as the natural spline with 5 degrees of freedom. Interaction effects between age and sex, sex and 495 study were also included in the regression model. Estimated ICV at each age was retained for the 496 following analysis. Next, linear mixed effect regression model with random intercept and slope 497 was fitted for total GMV. Basis function involving centered age was determined to be B spline 498 with 12 degrees of freedom. Interaction effects between age and sex, sex and study were 499 included in the regression model. Peak total GMV was defined as the highest total GMV one can 500 achieve during brain maturation.

501

502 **Comparisons of environmental burden, neurocognition, behavior and mental disorder** To 503 assess whether environmental burden, neurocognition, behavioral risk factors and mental 504 symptoms differ by groups, we analyzed their longitudinal measurements at 14y, 16y, 19y and

505 23y in IMAGEN. Personal traits, including personality, temperament and characters, were 506 obtained from the NEO Five-Factor Inventory (NEO-FFI) and temperament and character 507 inventory (TCI-R). Environmental burden, including prenatal exposures (parental smoking, 508 maternal drinking and maternal medical problems during pregnancy), birthweight, stressful life 509 events, child trauma experiences, child's experience of family life and family stressors, were 510 obtained from Pregnancy and Birth Questionnaire (PBQ), life-events questionnaire (LEQ), 511 Childhood Trauma Questionnaire (CTQ), and Family Stress Scale and Family Life Questionnaire 512 from development well-being assessment interview (DAWBA). Neurocognitive performances 513 were obtained from Cambridge Neuropsychological Test Automated Battery (CANTAB) tests, 514 Monetary-Choice Questionnaire (KIRBY) and Stop Signal Task (SST) results. Behavioral 515 assessments, including conduct problems and substance use, were obtained from strengths and 516 difficulties questionnaire (SDQ), European school survey project on alcohol and drugs (ESPAD), 517 Fagerstrom test for nicotine dependence (FTND). Mental health conditions, including ADHD 518 and depression, were obtained from self-rated development well-being assessment interview 519 (DAWBA), where Attention-deficit/hyperactivity disorder (ADHD) score was additionally 520 calculated using parent-rated interview. A detailed description of these assessment instruments is 521 provided in Supplementary Methods. Generalized linear models adjusting for sex, handedness 522 and ICV were used for comparing these tests at baseline and at the last follow-up visit (19y for 523 Pattern recognition memory (PRM), Affective Go-No Go (AGN) and Rapid visual information 524 processing (RVP); 23y for all other tests). For child-rated ADHD and depression score, baseline 525 scores were also included as covariates. Intra-Extra Dimensional Set Shift (IED) test was only 526 available at age 23y, and parent-rated ADHD score was only available at 14y and 16y. Cohen's d 527 was calculated for each measurement after regressing out the covariates. False discovery rate 528 (FDR) was used to correct for multiple testing within scales.

529

530 **Quality control of genomic data** In this study, we performed stringent QC standards using 531 PLINK 1.90. Individuals with > 10% missing rate and single-nucleotide polymorphisms (SNPs) 532 with call rates < 95%, minor allele frequency < 0.1%, deviation from the Hardy-Weinberg 533 equilibrium with P < 1E-10 were excluded from the analysis. For ABCD, we only selected 534 subjects with self-reporting White ancestral origins using the public release 3.0 imputed 535 genotype data, which was imputed with the HRC reference panel<sup>87</sup>. Considering that ABCD is

536 oversampled for siblings and twins, we randomly selected one participant within each family. 537 For IMAGEN, details about preprocessing of genomic data can be found in previous reports<sup>88</sup> 538 and data was imputed with the HapMap3 reference panel<sup>89</sup>. For UKB, we selected subjects that 539 were estimated to have recent British ancestry and have no more than ten putative third-degree 540 relatives in the kinship table using the sample quality control information provided by UKB. For 541 more details, please refer to the official document for genetic data of the UKB 542 (http://www.ukbiobank.ac.uk/scientists-3/genetic-data/). After quality control, we obtained a 543 total of 4,244,228 SNPs and 7,662 participants in ABCD, 5,966,316 SNPs and 1,982 participants 544 in IMAGEN, and 616,339 SNPs and 337,199 participants in UKB.

545

546 Calculation of genetic liability For each individual, polygenic risk scores (PRS) of ADHD, 547 ASD, EA and IQ were calculated based on the public GWAS summary statistics<sup>51,90-92</sup> using 548 PRSice v2.3.3. For ADHD, ASD and IQ, optimal p-value thresholds were determined based on 549 the best-fit R2 using parent-rated psychiatric scores for ADHD and ASD, and the total WISCIV 550 score. For EA, variants were selected using a P value threshold from 5e-08 to 1 with a step of 5e-551 05 and an average score under each P value threshold was calculated.

552

553 GWAS and validation Since it was difficult to estimate individual GMV developmental 554 trajectory in ABCD with limited number of structural MRI scans per participant and limited age 555 range, we calculated the group-reweighted GMV as a proxy phenotype. There are several 556 underlying assumptions in this calculation. Firstly, it assumes that all brain regions exhibit a 557 comparable linear change from childhood to adolescence. Secondly, it assumes that the 558 participants from ABCD and IMAGEN are drawn from a homogeneous population. Once again, 559 we only included individuals in ABCD with self-report White ancestral origins. ROI-specific 560 loading contributing to group classification (Group 2 vs Group 1, Group 3 vs Group 1, Group 3 561 vs Group 2, and Group 3 vs Groups 1/2) were obtained by regressing baseline GMV in 44 ROIs 562 adjusting for age, sex, handedness and site in IMAGEN. Logistic regression model was used as 563 the classification model and top 10 ROIs with the largest loadings were used to calculate the 564 group-reweighted GMV in ABCD. Since results remained similar when comparing Group 3 vs Group 1 and when comparing Group 3 vs Group 2 (Supplementary Figs. 17-18), we combined 565 566 Group 1 and 2 for increased statistical power, and performed the GWAS to investigate the

567 genetic variations associated with Group 3 vs Groups 1/2 (delayed brain development). GWAS 568 was conducted in the White population adjusting for sex, scanner effect and top 20 PCA 569 components using Plink 2 (Supplementary Fig. 19). To ensure the validity of group reweighted 570 phenotype, we correlated the Group-3 reweighted GMV and neurocognitive assessments (Game 571 of Dice Task, Delay Discounting Task and NIH Toolbox) in ABCD (Supplementary Methods). 572 Gene-based association analysis was conducted via MAGMA (version 1.10) using raw genomics 573 data with the same covariate adjustment. To validate the GWAS results, polygenic risk scores for 574 SNPs residing in CENPW (referred to as CENPW score) and across the whole genome (referred 575 to as PRS) were calculated. Four SNPs were obtained by clumping within 250 kb upstream and 576 downstream of CENPW (chr6:126339789-126483320) using Plink 2. PRS was calculated using 577 PRSice using the most predictive P threshold for group-reweighted baseline GMV (r=0.06, 578 P=0.033). Distribution of PRS between Group 3 vs Groups 1/2 and correlation coefficients 579 between PRS and neurocognition, behavior and mental disorder at age 14y and 23y were 580 obtained. FDR was used for multiple tests correction within scales.

581

582 EWAS, gene-specific methylation analysis and results validation. EWAS was performed 583 among 909 adolescents in Group 1 and Group 2 in IMAGEN. Methylation data were collected 584 using the Illumina Infinium HumanMethylation450 BeadChip. Locus-specific genome-wise 585 methylation analysis was conducted and beta values at each Autosomal CpG site between groups 586 was compared using logistic regression adjusting for sex, experimental batches (recruitment 587 center and acquisition wave), the first two principal components of methylation composition and 588 the first four principal components of estimated differential cell counts. Statistical significance 589 was set as false discovery rate (FDR) adjusted p-value < 0.05. Next, we aimed to investigate the 590 association between CpG site and gene methylation with environmental factors of interest. We 591 conducted mediation analyses (sem function in the lavaan 0.6-12 package) and estimated the 592 total effect of childhood experiences on estimated peak GMV and the indirect effect mediated by 593 cg06064461 hypermethylation. Sex, batches effects, methylation composition components and 594 differential cell count components were included as covariates. Total, direct and indirect effect 595 and their standard deviations were estimated using 1000-iterated nonparametric bootstrap 596 approach. False discovery rate (FDR) was used to correct for multiple testing within scales.

597

598 Long-term impacts of neurodevelopment in UK Biobank Socio-economic, cognitive and 599 mental health outcomes were obtained at baseline visit among participants in UK Biobank. 600 Socioeconomic conditions were assessed by household income, jobs involved in physical activity 601 and Indices of Multiple Deprivation (IMD) (education, employment and income scores). 602 Cognition was assessed by fluid intelligence and the highest educational attainment. The 603 educational level was divided into four ordinal categories: (1) College or University degree; (2) 604 A levels/AS levels, NVQ or HND or HNC, other professional qualifications or equivalent; (3) O 605 levels/GCSEs, CSEs or equivalent; (4) None of the above. Mental health was assessed by 606 diagnosis of mental disorders (anxiety, depression and mania), summary score of neuroticism 607 and self-reported mental symptom appearances. A detailed description of assessment instruments 608 used in the analysis can be found in Supplementary Methods. To estimate the long-term effect of 609 delayed neurodevelopment, we calculated CENPW score and RPS according to the results of 610 Group 3 GWAS and correlated these scores with outcomes of interest after regressing out the age 611 effect at recruitment, site and gender. It should be noted that these scores only reflect a genetic 612 predicted risk for delayed brain development. Given the large age gap between participants in 613 UK Biobank and IMAGEN, it is challenging to disentangle the long-term impacts of 614 neurodevelopment from those due to potential environmental confounding in mid-to-late 615 adulthood. Therefore, this analysis only serves to explore the potential long-term influence of 616 genetically predicted delayed neurodevelopment and does not account for potential confounding 617 due to environmental factors. Similarly, we assume the homogeneity of study populations 618 between IMAGEN and UK Biobank. For PRS calculation, we used P value thresholds from 5E-619 08 to 1 with a step of 5E-05 and calculated an average PRS score for each individual. Due to the 620 large sample size and easily-obtainable statistical significance, inferiority tests against 0.05 were 621 conducted against the null hypothesis that the absolute correlation coefficient was less than 0.05.

622

#### 623 Data availability

Data from the ABCD study are available from a dedicated database: https://abcdstudy.org/ by applicaton; data from the IMAGEN study are available upon application: https://imagen2.cea.fr; HCP data are available from: https://www.humanconnectome.org/ by applicaton; PNC data are available from dbGaP: https://www.ncbi.nlm.nih.gov/projects/gap/cgibin/study.cgi?study\_id=phs000607.v3.p2 by application; and UKB data are available from

- 629 https://biobank.ndph.ox.ac.uk/ by application ID 19542. Summary statistics from published
- 630 GWAS of ADHD, ASD, EA and IQ are available at https://atlas.ctglab.nl/. Summary statistics of
- the GWAS for delayed brain development in this study will be uploaded to <u>https://atlas.ctglab.nl/</u>
- 632 upon publication.
- 633

#### 634 Code availability

- 635 Primary analyses were conducted in R v4.2.2. Linear mixed effect models were performed using
- 636 *lme4* 1.1-31 and *nlme* 3.1-160 R packages. Mediation analysis was performed using *lavaan* 0.6-
- 637 12 R package. PLINK 2.0 was used to perform GWAS and calculate CENPW score. MAGMA
- 638 v1.10 was used to perform the gene-based association analysis. PRSice v2.3.3 was used to
- 639 calculate the PRS. Custom code that supports the main findings of this study will be available
- 640 https://github.com/abnmsry. Additional information related to this paper are available from the
- 641 authors upon reasonable request.
- 642

## 643 **Reference**644

- 645 1 Giedd, J. N. *et al.* Brain development during childhood and adolescence: a longitudinal
  646 MRI study. *Nat Neurosci* 2, 861-863, doi:10.1038/13158 (1999).
- Lenroot, R. K. & Giedd, J. N. Brain development in children and adolescents: insights
  from anatomical magnetic resonance imaging. *Neurosci Biobehav Rev* 30, 718-729,
  doi:10.1016/j.neubiorev.2006.06.001 (2006).
- Tamnes, C. K. *et al.* Development of the Cerebral Cortex across Adolescence: A
  Multisample Study of Inter-Related Longitudinal Changes in Cortical Volume, Surface
  Area, and Thickness. *J Neurosci* 37, 3402-3412, doi:10.1523/JNEUROSCI.3302-16.2017
  (2017).
- Paus, T., Keshavan, M. & Giedd, J. N. Why do many psychiatric disorders emerge during
  adolescence? *Nat Rev Neurosci* 9, 947-957, doi:10.1038/nrn2513 (2008).
- 6565Lee, F. S. *et al.* Adolescent mental health-Opportunity and obligation.**346**, 547-549,657doi:doi:10.1126/science.1260497 (2014).
- 6586Blakemore, S. J. Adolescence and mental health. Lancet**393**, 2030-2031,659doi:10.1016/S0140-6736(19)31013-X (2019).
- 660 7 Gunnell, D., Kidger, J. & Elvidge, H. Adolescent mental health in crisis. *BMJ* 361, k2608, doi:10.1136/bmj.k2608 (2018).
- Haier, R. J., Jung, R. E., Yeo, R. A., Head, K. & Alkire, M. T. Structural brain variation
  and general intelligence. *Neuroimage* 23, 425-433,
  doi:10.1016/j.neuroimage.2004.04.025 (2004).
- 9 665 Shaw, P. et al. Attention-deficit/hyperactivity disorder is characterized by a delay in 666 cortical maturation. Proc Natl Acad Sci US Α 104, 19649-19654, 667 doi:10.1073/pnas.0707741104 (2007).

- Shaw, P. *et al.* Intellectual ability and cortical development in children and adolescents. *Nature* 440, 676-679, doi:10.1038/nature04513 (2006).
- 670 Giedd, J. N. & Rapoport, J. L. Structural MRI of pediatric brain development: what have 11 671 learned and where are we going? Neuron **67**, 728-734, we doi:10.1016/j.neuron.2010.08.040 (2010). 672
- Ramsden, S. *et al.* Verbal and non-verbal intelligence changes in the teenage brain. *Nature* 479, 113-116, doi:10.1038/nature10514 (2011).
- Schnack, H. G. *et al.* Accelerated Brain Aging in Schizophrenia: A Longitudinal Pattern
  Recognition Study. *Am J Psychiatry* **173**, 607-616, doi:10.1176/appi.ajp.2015.15070922
  (2016).
- Bos, M. G. N., Peters, S., van de Kamp, F. C., Crone, E. A. & Tamnes, C. K. Emerging
  depression in adolescence coincides with accelerated frontal cortical thinning. *J Child Psychol Psychiatry* 59, 994-1002, doi:10.1111/jcpp.12895 (2018).
- Baum, G. L. *et al.* Development of structure-function coupling in human brain networks during youth. *Proc Natl Acad Sci U S A* **117**, 771-778, doi:10.1073/pnas.1912034117
  (2020).
- Sakai, J. Core Concept: How synaptic pruning shapes neural wiring during development
  and, possibly, in disease. *Proc Natl Acad Sci U S A* **117**, 16096-16099,
  doi:10.1073/pnas.2010281117 (2020).
- Hedman, A. M., van Haren, N. E., Schnack, H. G., Kahn, R. S. & Hulshoff Pol, H. E.
  Human brain changes across the life span: a review of 56 longitudinal magnetic resonance imaging studies. *Hum Brain Mapp* 33, 1987-2002, doi:10.1002/hbm.21334 (2012).
- Foulkes, L. & Blakemore, S. J. Studying individual differences in human adolescent
  brain development. *Nat Neurosci* 21, 315-323, doi:10.1038/s41593-018-0078-4 (2018).
- 69319Mills, K. L. *et al.* Inter-individual variability in structural brain development from late694childhood to young adulthood. Neuroimage242, 118450,695doi:10.1016/j.neuroimage.2021.118450 (2021).
- Sisk, C. L. & Foster, D. L. The neural basis of puberty and adolescence. *Nat Neurosci* 7, 1040-1047, doi:10.1038/nn1326 (2004).
- 698 21 Gogtay, N. *et al.* Dynamic mapping of human cortical development during childhood
  699 through early adulthood. *Proc Natl Acad Sci U S A* 101, 8174-8179,
  700 doi:10.1073/pnas.0402680101 (2004).
- Sowell, E. R. *et al.* Mapping cortical change across the human life span. *Nat Neurosci* 6, 309-315, doi:10.1038/nn1008 (2003).
- Noble, K. G. *et al.* Family income, parental education and brain structure in children and adolescents. *Nat Neurosci* 18, 773-778, doi:10.1038/nn.3983 (2015).
- 70524Rosenberg, M. D. et al. A neuromarker of sustained attention from whole-brain706functional connectivity. Nat Neurosci 19, 165-171, doi:10.1038/nn.4179 (2016).
- Mills, K. L. *et al.* Structural brain development between childhood and adulthood:
  Convergence across four longitudinal samples. *Neuroimage* 141, 273-281,
  doi:10.1016/j.neuroimage.2016.07.044 (2016).
- Brouwer, R. M. *et al.* Genetic variants associated with longitudinal changes in brain
  structure across the lifespan. *Nat Neurosci* 25, 421-432, doi:10.1038/s41593-022-01042-4
  (2022).

- 713 27 Deary, I. J. *et al.* Genetic contributions to stability and change in intelligence from childhood to old age. *Nature* **482**, 212-215, doi:10.1038/nature10781 (2012).
- 715 28 Bethlehem, R. A. I. *et al.* Brain charts for the human lifespan. *Nature* 604, 525-533,
  716 doi:10.1038/s41586-022-04554-y (2022).
- Jack, C. R., Jr. *et al.* Tracking pathophysiological processes in Alzheimer's disease: an
  updated hypothetical model of dynamic biomarkers. *Lancet Neurol* 12, 207-216,
  doi:10.1016/S1474-4422(12)70291-0 (2013).
- 72030Abi-Dargham, A. & Horga, G. The search for imaging biomarkers in psychiatric721disorders. Nat Med 22, 1248-1255, doi:10.1038/nm.4190 (2016).
- Schmaal, L. *et al.* Cortical abnormalities in adults and adolescents with major depression
  based on brain scans from 20 cohorts worldwide in the ENIGMA Major Depressive
  Disorder Working Group. *Mol Psychiatry* 22, 900-909, doi:10.1038/mp.2016.60 (2017).
- Radua, J. *et al.* Ventral Striatal Activation During Reward Processing in Psychosis: A
  Neurofunctional Meta-Analysis. *JAMA Psychiatry* 72, 1243-1251,
  doi:10.1001/jamapsychiatry.2015.2196 (2015).
- Mayberg, H. S. *et al.* Reciprocal limbic-cortical function and negative mood: converging
  PET findings in depression and normal sadness. *Am J Psychiatry* 156, 675-682,
  doi:10.1176/ajp.156.5.675 (1999).
- Shafee, R., Buckner, R. L. & Fischl, B. Gray matter myelination of 1555 human brains
  using partial volume corrected MRI images. *Neuroimage* 105, 473-485,
  doi:10.1016/j.neuroimage.2014.10.054 (2015).
- 73435Corrigan, N. M. et al. Myelin development in cerebral gray and white matter during735adolescence and late childhood. Neuroimage227, 117678,736doi:10.1016/j.neuroimage.2020.117678 (2021).
- Zatorre, R. J., Fields, R. D. & Johansen-Berg, H. Plasticity in gray and white:
  neuroimaging changes in brain structure during learning. *Nat Neurosci* 15, 528-536,
  doi:10.1038/nn.3045 (2012).
- Schmidt, S. *et al.* Experience-dependent structural plasticity in the adult brain: How the learning brain grows. *Neuroimage* 225, 117502, doi:10.1016/j.neuroimage.2020.117502
  (2021).
- Whitaker, K. J. *et al.* Adolescence is associated with genomically patterned consolidation
  of the hubs of the human brain connectome. *Proc Natl Acad Sci U S A* **113**, 9105-9110,
  doi:10.1073/pnas.1601745113 (2016).
- 74639Mascarell Maricic, L. *et al.* The IMAGEN study: a decade of imaging genetics in<br/>adolescents. *Mol Psychiatry* **25**, 2648-2671, doi:10.1038/s41380-020-0822-5 (2020).
- 74840Hori, T. *et al.* CCAN makes multiple contacts with centromeric DNA to provide distinct749pathways to the outer kinetochore. *Cell* **135**, 1039-1052, doi:10.1016/j.cell.2008.10.019750(2008).
- 75141Nishino, T. *et al.* CENP-T-W-S-X forms a unique centromeric chromatin structure with a752histone-like fold. *Cell* 148, 487-501, doi:10.1016/j.cell.2011.11.061 (2012).
- 75342Aygun, N. *et al.* Brain-trait-associated variants impact cell-type-specific gene regulation754during neurogenesis. Am J Hum Genet 108, 1647-1668, doi:10.1016/j.ajhg.2021.07.011755(2021).
- Zhao, B. *et al.* Genome-wide association analysis of 19,629 individuals identifies variants
   influencing regional brain volumes and refines their genetic co- architecture with

cognitive and mental health traits. *Nat Genet* 51, 1637-1644, doi:10.1038/s41588-0190516-6 (2019).

- Shin, J. *et al.* Global and Regional Development of the Human Cerebral Cortex:
  Molecular Architecture and Occupational Aptitudes. *Cereb Cortex* 30, 4121-4139,
  doi:10.1093/cercor/bhaa035 (2020).
- Grasby, K. L. *et al.* The genetic architecture of the human cerebral cortex. *Science* 367, doi:10.1126/science.aay6690 (2020).
- 765 46 Hofer, E. et al. Genetic correlations and genome-wide associations of cortical structure in 766 population samples of 22,824 adults. 11. 4796. general Nat Commun 767 doi:10.1038/s41467-020-18367-y (2020).
- 76847van der Meer, D. *et al.* Understanding the genetic determinants of the brain with769MOSTest. Nat Commun 11, 3512, doi:10.1038/s41467-020-17368-1 (2020).
- van der Meer, D. *et al.* The genetic architecture of human cortical folding. *Sci Adv* 7,
  eabj9446, doi:10.1126/sciadv.abj9446 (2021).
- 49 Davies, G. *et al.* Study of 300,486 individuals identifies 148 independent genetic loci influencing general cognitive function. *Nat Commun* 9, 2098, doi:10.1038/s41467-018-04362-x (2018).
- Hill, W. D. *et al.* A combined analysis of genetically correlated traits identifies 187 loci
  and a role for neurogenesis and myelination in intelligence. *Mol Psychiatry* 24, 169-181,
  doi:10.1038/s41380-017-0001-5 (2019).
- Lee, J. J. *et al.* Gene discovery and polygenic prediction from a genome-wide association
  study of educational attainment in 1.1 million individuals. *Nat Genet* 50, 1112-1121,
  doi:10.1038/s41588-018-0147-3 (2018).
- 52 Gudbjartsson, D. F. *et al.* Many sequence variants affecting diversity of adult human height. *Nat Genet* 40, 609-615, doi:10.1038/ng.122 (2008).
- 53 Berndt, S. I. *et al.* Genome-wide meta-analysis identifies 11 new loci for anthropometric
  traits and provides insights into genetic architecture. *Nat Genet* 45, 501-512,
  doi:10.1038/ng.2606 (2013).
- van der Valk, R. J. *et al.* A novel common variant in DCST2 is associated with length in
  early life and height in adulthood. *Human molecular genetics* 24, 1155-1168,
  doi:10.1093/hmg/ddu510 (2015).
- 55 Shungin, D. *et al.* New genetic loci link adipose and insulin biology to body fat distribution. *Nature* 518, 187-196, doi:10.1038/nature14132 (2015).
- 791 56 Tachmazidou, I. *et al.* Whole-Genome Sequencing Coupled to Imputation Discovers
  792 Genetic Signals for Anthropometric Traits. *Am J Hum Genet* 100, 865-884,
  793 doi:10.1016/j.ajhg.2017.04.014 (2017).
- Pearson, A. G., Curtis, M. A., Waldvogel, H. J., Faull, R. L. & Dragunow, M. Activating
  transcription factor 2 expression in the adult human brain: association with both
  neurodegeneration and neurogenesis. *Neuroscience* 133, 437-451,
  doi:10.1016/j.neuroscience.2005.02.029 (2005).
- Suzuki, T., Yamakuni, T., Hagiwara, M. & Ichinose, H. Identification of ATF-2 as a transcriptional regulator for the tyrosine hydroxylase gene. *J Biol Chem* 277, 40768-40774, doi:10.1074/jbc.M206043200 (2002).
- Watson, G., Ronai, Z. A. & Lau, E. ATF2, a paradigm of the multifaceted regulation of transcription factors in biology and disease. *Pharmacol Res* 119, 347-357, doi:10.1016/j.phrs.2017.02.004 (2017).


- Islam, A., Mohammad, E. & Khan, M. A. Aberration of the modulatory functions of intronic microRNA hsa-miR-933 on its host gene ATF2 results in type II diabetes mellitus and neurodegenerative disease development. *Hum Genomics* 14, 34, doi:10.1186/s40246-020-00285-1 (2020).
- 808 61 Bellina, M. *et al.* Relationship between parenting measures and parents and child
  809 psychopathological symptoms: a cross-sectional study. *BMC Psychiatry* 20, 377,
  810 doi:10.1186/s12888-020-02778-8 (2020).
- 811 62 Hagenaars, S. P. *et al.* Shared genetic aetiology between cognitive functions and physical
  812 and mental health in UK Biobank (N=112 151) and 24 GWAS consortia. *Mol Psychiatry*813 21, 1624-1632, doi:10.1038/mp.2015.225 (2016).
- Bid Hagenaars, S. P. *et al.* Genetic contributions to Trail Making Test performance in UK
  Biobank. *Mol Psychiatry* 23, 1575-1583, doi:10.1038/mp.2017.189 (2018).
- 816 64 Warrier, V. *et al.* Gene-environment correlations and causal effects of childhood
  817 maltreatment on physical and mental health: a genetically informed approach. *Lancet*818 *Psychiatry* 8, 373-386, doi:10.1016/S2215-0366(20)30569-1 (2021).
- Hughes, K. *et al.* The effect of multiple adverse childhood experiences on health: a
  systematic review and meta-analysis. *Lancet Public Health* 2, e356-e366,
  doi:10.1016/S2468-2667(17)30118-4 (2017).
- 822 66 Sawyer, S. M. *et al.* Adolescence: a foundation for future health. *Lancet* 379, 1630-1640, doi:10.1016/S0140-6736(12)60072-5 (2012).
- 824 67 World Health, O. (World Health Organization, Geneva, 2001).
- 825 68 Worthman, C. M. & Trang, K. Dynamics of body time, social time and life history at adolescence. *Nature* 554, 451-457, doi:10.1038/nature25750 (2018).
- Hensch, T. K. Critical period plasticity in local cortical circuits. *Nat Rev Neurosci* 6, 877828 888, doi:10.1038/nrn1787 (2005).
- Response for the second seco
- Drzewiecki, C. M., Willing, J. & Juraska, J. M. Synaptic number changes in the medial
  prefrontal cortex across adolescence in male and female rats: A role for pubertal onset. *Synapse* 70, 361-368, doi:10.1002/syn.21909 (2016).
- Petanjek, Z. *et al.* Extraordinary neoteny of synaptic spines in the human prefrontal cortex. *Proc Natl Acad Sci U S A* **108**, 13281-13286, doi:10.1073/pnas.1105108108
  (2011).
- Zuo, Y., Lin, A., Chang, P. & Gan, W. B. Development of long-term dendritic spine
  stability in diverse regions of cerebral cortex. *Neuron* 46, 181-189,
  doi:10.1016/j.neuron.2005.04.001 (2005).
- Response to the second secon
- 75 Davidow, J. Y., Foerde, K., Galvan, A. & Shohamy, D. An Upside to Reward Sensitivity:
  844 The Hippocampus Supports Enhanced Reinforcement Learning in Adolescence. *Neuron*845 92, 93-99, doi:10.1016/j.neuron.2016.08.031 (2016).
- van den Bos, W., Cohen, M. X., Kahnt, T. & Crone, E. A. Striatum-medial prefrontal cortex connectivity predicts developmental changes in reinforcement learning. *Cereb Cortex* 22, 1247-1255, doi:10.1093/cercor/bhr198 (2012).

- Hauser, T. U., Iannaccone, R., Walitza, S., Brandeis, D. & Brem, S. Cognitive flexibility
  in adolescence: neural and behavioral mechanisms of reward prediction error processing
  in adaptive decision making during development. *Neuroimage* 104, 347-354,
  doi:10.1016/j.neuroimage.2014.09.018 (2015).
- 853 78 Ernst, M., Moolchan, E. T. & Robinson, M. L. Behavioral and neural consequences of
  854 prenatal exposure to nicotine. *J Am Acad Child Adolesc Psychiatry* 40, 630-641,
  855 doi:10.1097/00004583-200106000-00007 (2001).
- Bookstein, F. L., Streissguth, A. P., Sampson, P. D., Connor, P. D. & Barr, H. M. Corpus
  callosum shape and neuropsychological deficits in adult males with heavy fetal alcohol
  exposure. *Neuroimage* 15, 233-251, doi:10.1006/nimg.2001.0977 (2002).
- 859 80 Sowell, E. R. *et al.* Abnormal cortical thickness and brain-behavior correlation patterns in individuals with heavy prenatal alcohol exposure. *Cereb Cortex* 18, 136-144, doi:10.1093/cercor/bhm039 (2008).
- 862 81 Lees, B. *et al.* Association of Prenatal Alcohol Exposure With Psychological, Behavioral,
  863 and Neurodevelopmental Outcomes in Children From the Adolescent Brain Cognitive
  864 Development Study. *Am J Psychiatry* **177**, 1060-1072,
  865 doi:10.1176/appi.ajp.2020.20010086 (2020).
- 866 82 Bublitz, M. H. & Stroud, L. R. Childhood sexual abuse is associated with cortisol awakening response over pregnancy: preliminary findings. *Psychoneuroendocrinology* 37, 1425-1430, doi:10.1016/j.psyneuen.2012.01.009 (2012).
- 869 83 Roussotte, F. F. *et al.* Regional brain volume reductions relate to facial dysmorphology
  870 and neurocognitive function in fetal alcohol spectrum disorders. *Hum Brain Mapp* 33,
  871 920-937, doi:10.1002/hbm.21260 (2012).
- 872 84 Dazzan, P. & Murray, R. M. Neurological soft signs in first-episode psychosis: a
  873 systematic review. *Br J Psychiatry Suppl* 43, s50-57, doi:10.1192/bjp.181.43.s50 (2002).
- 874 85 Schroder, J. & Toro, P. Neurological soft signs predict outcomes in schizophrenia. *Nat*875 *Rev Neurol* 16, 659-660, doi:10.1038/s41582-020-0403-x (2020).
- 86 Seidl, U., Thomann, P. A. & Schroder, J. Neurological soft signs in nursing home
  877 residents with Alzheimer's disease. J Alzheimers Dis 18, 525-532, doi:10.3233/JAD878 2009-1159 (2009).
- 879 87 McCarthy, S. *et al.* A reference panel of 64,976 haplotypes for genotype imputation. *Nat*880 *Genet* 48, 1279-1283, doi:10.1038/ng.3643 (2016).
- 881 88 Luo, Q. *et al.* Association of a Schizophrenia-Risk Nonsynonymous Variant With
  882 Putamen Volume in Adolescents: A Voxelwise and Genome-Wide Association Study.
  883 JAMA Psychiatry 76, 435-445, doi:10.1001/jamapsychiatry.2018.4126 (2019).
- 884 89 International HapMap, C. *et al.* Integrating common and rare genetic variation in diverse
  885 human populations. *Nature* 467, 52-58, doi:10.1038/nature09298 (2010).
- Bernontis, D. *et al.* Discovery of the first genome-wide significant risk loci for attention deficit/hyperactivity disorder. *Nat Genet* 51, 63-75, doi:10.1038/s41588-018-0269-7
  (2019).
- 889 91 Grove, J. *et al.* Identification of common genetic risk variants for autism spectrum disorder. *Nat Genet* 51, 431-444, doi:10.1038/s41588-019-0344-8 (2019).
- 891 92 Savage, J. E. *et al.* Genome-wide association meta-analysis in 269,867 individuals
  892 identifies new genetic and functional links to intelligence. *Nat Genet* 50, 912-919,
  893 doi:10.1038/s41588-018-0152-6 (2018).
- 894

- 895
- 896
- 897


898 899 **Acknowledgments and funding:** This work received support from the following sources: 900 National Key R&D Program of China (No.2019YFA0709502), National Key R&D Program of 901 China (No.2018YFC1312904), Shanghai Municipal Science and Technology Major Project 902 (No.2018SHZDZX01), ZJ Lab, and Shanghai Center for Brain Science and Brain-Inspired 903 Technology, the 111 Project (No.B18015), the European Union-funded FP6 Integrated Project 904 IMAGEN (Reinforcement-related behaviour in normal brain function and psychopathology) 905 (LSHM-CT- 2007-037286), the Horizon 2020 funded ERC Advanced Grant 'STRATIFY' 906 (Brain network based stratification of reinforcement-related disorders) (695313), Human Brain 907 Project (HBP SGA 2, 785907, and HBP SGA 3, 945539), the Medical Research Council Grant 908 'c-VEDA' (Consortium on Vulnerability to Externalizing Disorders and Addictions) 909 (MR/N000390/1), the National Institute of Health (NIH) (R01DA049238, A decentralized macro 910 and micro gene-by-environment interaction analysis of substance use behavior and its brain 911 biomarkers), the National Institute for Health Research (NIHR) Biomedical Research Centre at 912 South London and Maudsley NHS Foundation Trust and King's College London, the 913 Bundesministeriumfür Bildung und Forschung (BMBF grants 01GS08152; 01EV0711; 914 Forschungsnetz AERIAL 01EE1406A, 01EE1406B; Forschungsnetz IMAC-Mind 01GL1745B), 915 the Deutsche Forschungsgemeinschaft (DFG grants SM 80/7-2, SFB 940, TRR 265, NE 916 1383/14-1), the Medical Research Foundation and Medical Research Council (grants 917 MR/R00465X/1 and MR/S020306/1), the National Institutes of Health (NIH) funded ENIGMA 918 (grants 5U54EB020403-05 and 1R56AG058854-01), NSFC grant 82150710554 and 919 environMENTAL grant. Further support was provided by grants from: - the ANR (ANR-12-920 SAMA-0004, AAPG2019 - GeBra), the Eranet Neuron (AF12-NEUR0008-01 - WM2NA; and 921 ANR-18-NEUR00002-01 - ADORe), the Fondation de France (00081242), the Fondation pour la 922 Recherche Médicale (DPA20140629802), the Mission Interministérielle de Lutte-contre-les-923 Drogues-et-les-Conduites-Addictives (MILDECA), the Assistance-Publique-Hôpitaux-de-Paris 924 and INSERM (interface grant), Paris Sud University IDEX 2012, the Fondation de l'Avenir 925 (grant AP-RM-17-013), the Fédération pour la Recherche sur le Cerveau; the National Institutes 926 of Health, Science Foundation Ireland (16/ERCD/3797), U.S.A. (Axon, Testosterone and Mental

- 927 Health during Adolescence; RO1 MH085772-01A1) and by NIH Consortium grant U54
- 928 EB020403, supported by a cross-NIH alliance that funds Big Data to Knowledge Centres of
- 929 Excellence. The funders had no role in study design, data collection and analysis, decision to
- 930 publish or preparation of the manuscript.
- 931 Competing Interests: Dr Banaschewski served in an advisory or consultancy role for Lundbeck,
- 932 Medice, Neurim Pharmaceuticals, Oberberg GmbH, Shire. He received conference support or
- 933 speaker's fee by Lilly, Medice, Novartis and Shire. He has been involved in clinical trials
- 934 conducted by Shire & Viforpharma. He received royalties from Hogrefe, Kohlhammer, CIP
- 935 Medien, Oxford University Press. The present work is unrelated to the above grants and
- 936 relationships. Dr Barker receives honoraria for teaching from GE Healthcare. Dr Poustka served
- 937 in an advisory or consultancy role for Roche and Viforpharm and received speaker's fee by Shire.
- 938 She received royalties from Hogrefe, Kohlhammer and Schattauer. The present work is unrelated
- 939 to the above grants and relationships. The other authors report no biomedical financial interests
- 940 or potential conflicts of interest.




#### Fig. 1 Whole-brain gray matter volume (GMV) developmental patterns define three neurodevelopmental groups.

(a) Schematic workflow of data sets and analytic methodologies. GMV trajectory in 44 ROIs spanning the cortical and subcortical areas was estimated using linear mixed effect models for adolescents in the IMAGEN study (n=1,543). Principal component analysis and multivariate clustering were conducted to identify groups with distinct neurodevelopmental patterns. Next, groups were characterized in terms of neurocognition and risk factors for neuropsychiatric disorders. Genome-wide association study (GWAS) was conducted in the ABCD study (n=7,662) using group-reweighted GMV as the proxy phenotype for delayed neurodevelopment, and results were further validated in IMAGEN. Epigenome-wide association study (EWAS) was conducted in IMAGEN (n=909) to identify potential environmental exposures associated with neurodevelopment. Last, long-term impacts of the polygenic risk for delayed neurodevelopment on multiple outcomes were investigated among participants in UK Biobank (n=502,486) (Methods). BL, baseline; FU1, follow-up 1 at 16 y; FU2, follow-up 1 at 19 y; FU3, follow-up 1 at 23 y. (b) Whole-brain GMV growth rates (ranging from increase, stable to decrease) at age 5y, 10y, 15y, 20y and 25y were estimated for each group identified in IMAGEN, adjusting for sex, imaging site, handedness and intra-cranial volume (Methods). Group 3 showed delayed GMV development compared to Group 1 and 2. (c) Total GMV developmental trajectories (with 95% confidence bands) for the three groups identified in the IMAGEN study (Group 1-3). These trajectories were estimated adjusting for sex, imaging site, handedness and intra-cranial volume (Methods). Group 1 and 2 exhibited similar GMV developmental trend, while Group 3 had opposite GMV developmental trend. (d) The top 5 discriminating ROIs with largest t values comparing the GMV trajectories between Group 3 (n=67) and Group 1 (n=711) (top), and between Group 2 (n=765) and Group 1 (n=711) (bottom). adjusting for sex, imaging site, handedness and intra-cranial volume. Two sample t-test: Group 3 vs Group1, IFT (d=4.43, t=20.13, \*\*\* $P_{adj}$ <0.001), MT (d=4.38, t=20.07, \*\*\* $P_{adj}$ <0.001), LatOFC (d=4.26, t=18.31, \*\*\* $P_{adj}$ <0.001), PreC (d=3.63, t=18.11, \*\*\* $P_{adj}$ <0.001), SF (d=3.61, t=17.92, \*\*\* $P_{adj}$ <0.001); Group 2 vs Group 1, SF (d=1.28, t=24.50, \*\*\* $P_{adj}$ <0.001), RMF (d=1.14, t=21.95, \*\*\* $P_{adj}$ <0.001), CMF (d=1.09, t=20.77, \*\*\* $P_{adj}$ <0.001), PreC (d=1.05, t=20.14, \*\*\* $P_{adj}$ <0.001), IFP (d=1.00, t=19.07, \*\*\* $P_{adj}$ <0.001). LatOFC, lateral orbitofrontal cortex; RMF, rostral middle frontal; CMF, caudal middle frontal; SF, superior frontal; PreC, precentral; MT, middle temporal; IFT, inferior temporal; IFP, inferior parietal.




#### Fig. 2 Structural neurodevelopment predicts neurocognition and risk factors for neuropsychiatric disorders.

(a) Comparison of neurocognitive performances between Group 3 and Group 1 (orange), and between Group 2 and Group 1 (green) at baseline (BL) and the last follow-up (FU) (**Methods**). Total number of neurocognitive tests in cantab where Group 3 performed worse than Group 1 decreased from 7/12 at baseline to 1/12 at follow-up 3, while the number of tests where Group 2 performed worse than Group 1 increased from 0 to 3/12. Full results with item-specific comparisons among these groups are provided in **Supplementary Fig. 7**. CANTAB, Cambridge Neuropsychological Test Automated Battery. (b) Longitudinal trajectories of Depression (Left) and ADHD symptoms (Right) among adolescents in the three groups. Group-specific means at each visit were plotted and \* indicated significant differences relative to Group 1 adjusting for sex, handedness, stie and ICV. Baseline mental health score was also adjusted for comparison at the last follow-up. Statistical tests were conducted at baseline (14y) and the last follow-up. Depression, Group 2 vs Group 1 at 14y (*d*=-0.01, *P*=0.566), Group 2 vs Group 1 at 23y (*d*=0.13, \**P*=0.023), Group 3 vs Group 1 at 14y (*d*=-0.01, *P*=0.566), Group 3 vs Group 1 at 14y (*d*=-0.03, *P*=0.574), Group 3 vs Group 1 at 14 y (*d*=0.34, \*\**P*=0.004), Group 3 vs Group 1 at 16y (*d*=0.01, *P*=0.954); Child rated ADHD, Group 2 vs Group 1 at 23y (*d*=0.02, *P*=0.758), Group 3 vs Group 1 at 14 y (*d*=0.34, *P*=\*0.042), Group 3 vs Group 1 at 14 y (*d*=0.34, *P*=\*0.042), Group 3 vs Group 1 at 14 y (*d*=-0.34).




### Fig. 3 Genome-wide association study (GWAS) identified two significant loci associated with delayed neurodevelopment in Group 3.

(a) Correlation between Group3-reweighted GMV and neurocognition (**Supplementary Methods**) in ABCD (n=11,101) indicated the validity of using the proxy phenotype for delayed neurodevelopment in the following GWAS. GDT, Game of Dice Task; DDT, Dealy Discounting Task; PVT, Picture Vocabulary Test; Flanker, Flanker Inhibitory Control and Attention Test; List, List Sorting Working Memory Test; DCCS, Dimensional Change Card Sort Test; Pattern, Pattern Comparison Processing Speed Test; PSMT, Picture Sequence Memory Test; Reading, Oral Reading Recognition Test; FluidCog, fluid cognition; CrystalCog, crystallized cognition; TotalCog, total cognition. \*\*\* P<0.01; \*\* P<0.01; \* P<0.05. (b) GWAS Manhattan plot for Group3-reweighted GMV in the ABCD population (n=7,662). Group3-reweighted GMV was calculated for each adolescent (**Methods**) and used as the proxy phenotype for delayed neurodevelopment. Multiple SNPs on chromosome 6 achieved genome-wide significant effects (P<5×10<sup>-8</sup>). SNPs on chromosome 6 were mapped to the intronic region of *CENPW*. Results from gene based association analysis (**Supplementary Fig. 11**) confirmed the significant effect of CENPW on delayed neurodevelopment. Box plot in (**c**) showed that *CENPW* score of delayed neurodevelopment was negatively correlated with baseline (BL) neurocognitive performance, and became non-significant at the last follow-up (FU). Here, *Worse* indicated higher CGT Delay aversion score, lower CGT risk adjustment score, longer CGT Delibration time and SST GoRT. CGT Delay aversion, BL (r=0.08,  $*P_{adj}$ =0.027), FU3 (r=0.022,  $P_{adj}$ =0.983); CGT risk adjustment, BL (r=-0.08,  $*P_{adj}$ =0.027), FU3 (r=0.022,  $P_{adj}$ =0.983); SST GoRT, BL (r=-0.06,  $*P_{adj}$ =0.038), FU3 (r=-0.03,  $P_{adj}$ =0.472). CGT, Cambridge Gambling Task; SST GoRT, reaction time for 'Go' trials in Stop Signal Task. (**c-d**) confirmed the relationship between *CENPW* and delayed neurodevelopment identified in (**b**).



### Fig. 4 Epigenome-wide association study (EWAS) identified significant signals associated with lowered neurodevelopment in Group 2.

(a) EWAS Manhattan plot in the IMAGEN population. Group 2 (n=463) (relative to Group 1, n=446) status was used as the phenotype, adjusting for potential confounders (**Methods**). One hypermethylated site cg06064461 achieved genome-wide significant effect (P<5×10<sup>-8</sup>,  $P_{adj}$ <0.05) and was mapped to *ATF2* and *MIR933* on chromosome 2. (**b-c**) Validation of EWAS results in IMAGEN (n=909). cg06064461 methylation was positively correlated with total GMV trajectory (**b**; r=0.14, \*\*\*P<0.001) and negatively correlated with peak gray matter volume (GMV) (**c**; r=-0.07, \*P=0.020), adjusting for potential confounders (**Methods**). (**d**) Proportion of the mediation effects through cg06064461 methylation in the environmental exposure - peak GMV pathway, adjusting for potential confounders. Environmental factors were sorted by P values of the mediation effects. Although none mediation effects of cg06064461 methylation showed statistical significance after correcting for multiple testing, nominal significance was observed between family affirmation and peak GMV. Childexp, child's experience of family life; FamStress, family stressors; CTQ, Childhood Trauma Questionnaire. (**e**) Mediation model was conducted to analyze the direct and indirect effect of family affirmation on peak GMV, with cg06064461 methylation as the mediator. Results showed that cg06064461 methylation significantly mediate the relationship between family affirmation and peak GMV ( $\beta$ =0.005, \*P=0.048).



## Fig. 5 Genetically-predicted neurodevelopment had limited impact on socio-economic, cognitive and mental health outcomes in mid-to-late adulthood.

(a) Correlation between polygenic risk score (PRS) of delayed neurodevelopment and total gray matter volume (GMV) for participants in UK Biobank (n=337,199). Marginal distributions of PRS and total GMV were both normal. PRS and CENPW score both showed negative correlation with total GMV(r=-0.07, \*\*\*P<0.001 for PRS and r=-0.07, \*\*\*P<0.001 for CENPW score). PRS were averaged over different P value thresholds. (b) Correlation between averaged PRS of delayed neurodevelopment and *CENPW* score and regional GMV for participants in UK Biobank. Inferior temporal (r=-0.07, \*\*\* $P_{adj}$ <0.001), fusiform (r=-0.06, \*\*\* $P_{adj}$ <0.001), middle temporal (r=-0.06, \*\*\* $P_{adj}$ <0.001), medialorbitofrontal (r=-0.06, \*\*\* $P_{adj}$ <0.001) and lateralorbitofrontal (r=-0.06, \*\*\* $P_{adj}$ <0.001) were among the ROIs with the strongest correlation with PRS, while lateralorbitofrontal (r=-0.06, \*\*\* $P_{adj}$ <0.001), caudalmiddlefrontal (r=-0.05, \*\*\* $P_{adj}$ <0.001), insula (r=-0.05, \*\*\* $P_{adj}$ <0.001), insula (r=-0.05, \*\*\* $P_{adj}$ <0.001), and superiorfrontal (r=-0.05, \*\*\* $P_{adj}$ <0.001) were ROIs having the strongest correlation with *CENPW* score. These were consistent with the results that participants with higher PRS of delayed neurodevelopment also had worse performance in spatial working memory in UK Biobank. (c) Inferiority test of the correlation between averaged PRS and socio-economic, cognitive and mental health outcomes (**Supplementary Methods**) indicated that polygenic risk of delayed neurodevelopment had limited effect on the long-term socio-economic, cognitive and mental health outcomes (**Supplementary Fig. 15**). IMD, Indices of Multiple Deprivation; Scot, Scotland; Edu, the highest educational level; IQ, intelligence.